Title:
CFTR阻害剤化合物およびそれらの使用
Document Type and Number:
Japanese Patent JP2010523579
Kind Code:
A
Abstract:
The present invention relates to compositions and methods for treating a disease in an animal, which disease is responsive to inhibiting of the functional cystic fibrosis transmembrane conductance regulator (CFTR) polypeptide by administering to a mammal in need thereof an effective amount of a cyclic or acyclic hydrazine derivative including those of formulas II or III: or compositions thereof, thereby treating the disease. The present invention particularly, relates to a method of treating diarrhea and polycystic kidney disease.
More Like This:
Inventors:
Russell, Michael Jeffrey Neil
Beta, hugh david
MacRitchie, Jack Lean Ann
Doyle, Kevin James
Brown, david
Peach, joanne
Beta, hugh david
MacRitchie, Jack Lean Ann
Doyle, Kevin James
Brown, david
Peach, joanne
Application Number:
JP2010502221A
Publication Date:
July 15, 2010
Filing Date:
March 28, 2008
Export Citation:
Assignee:
Institute for One World Health
International Classes:
C07C251/86; A61K31/16; A61K31/165; A61K31/166; A61K31/167; A61K31/18; A61K31/381; A61K31/385; A61K31/40; A61K31/402; A61K31/4045; A61K31/415; A61K31/4178; A61K31/421; A61K31/426; A61K31/433; A61K31/4418; A61K31/445; A61K31/4545; A61K31/47; A61K31/4709; A61K31/496; A61K31/50; A61K31/505; A61K31/517; A61K31/5415; A61P1/04; A61P1/12; A61P1/16; A61P1/18; A61P9/00; A61P9/06; A61P11/00; A61P11/02; A61P11/06; A61P11/16; A61P13/12; A61P15/08; A61P43/00; C07C271/22; C07C311/08; C07C311/21; C07C317/44; C07C323/62; C07D207/325; C07D209/08; C07D209/42; C07D211/62; C07D213/74; C07D213/86; C07D215/36; C07D215/52; C07D231/06; C07D231/14; C07D237/04; C07D239/28; C07D239/92; C07D263/34; C07D277/06; C07D277/20; C07D277/30; C07D277/56; C07D279/36; C07D285/06; C07D295/18; C07D333/16; C07D333/38; C07D333/70; C07D339/06; C07D401/04; C07D405/06; C07D409/04; C07D495/04
Domestic Patent References:
| JPH03141264A | 1991-06-17 | |||
| JPS5826803A | 1983-02-17 | |||
| JPS5093984A | 1975-07-26 | |||
| JPS62142165A | 1987-06-25 | |||
| JPS5312879A | 1978-02-04 | |||
| JPS53111085A | 1978-09-28 | |||
| JP2010013354A | 2010-01-21 | |||
| JPS60501258A | 1985-08-08 | |||
| JP2006521381A | 2006-09-21 | |||
| JP2009544709A | 2009-12-17 | |||
| JP2009518323A | 2009-05-07 |
Foreign References:
| WO2005037773A1 | 2005-04-28 | |||
| WO2005094374A2 | 2005-10-13 | |||
| WO2007019933A1 | 2007-02-22 | |||
| WO2006060127A2 | 2006-06-08 | |||
| US4888423A | 1989-12-19 | |||
| US4397854A | 1983-08-09 |
Other References:
JPN6013025462; Ｃｈａｔｃｈａｉ Ｍｕａｎｐｒａｓａｔ ｅｔ ａｌ．: Ｊ． Ｇｅｎ． Ｐｈｙｓｉｏｌ． Ｖｏｌ．１２４, 2004, ｐ．１２５-１３７
JPN6013025463; Ｍａｒｇａｒｅｔ Ａ． ＭｃＰｈｅｒｓｏｎ ｅｔ ａｌ．: ＦＥＢＳ Ｌｅｔｔｅｒｓ Ｖｏｌ．４６４, 1999, ｐ．４８-５２
JPN6013025460; Ｆｒａｎｃｏ Ｃｈｉｍｅｎｔｉ ｅｔ ａｌ．: Ｃｈｅｍ Ｂｉｏｌ Ｄｒｕｇ Ｄｅｓ Ｖｏｌ．６７, 2006, ｐ．２０６-２１４
JPN6013025461; Ｎ． Ｋａｌｙａｎａｍ ｅｔ ａｌ．: Ｓｙｎｔｈｅｔｉｃ Ｃｏｍｍｕｎｉｃａｔｉｏｎｓ Ｖｏｌ．１８（１６＆１７）, 1988, ｐ．２１８３-２１９１
JPN6013025463; Ｍａｒｇａｒｅｔ Ａ． ＭｃＰｈｅｒｓｏｎ ｅｔ ａｌ．: ＦＥＢＳ Ｌｅｔｔｅｒｓ Ｖｏｌ．４６４, 1999, ｐ．４８-５２
JPN6013025460; Ｆｒａｎｃｏ Ｃｈｉｍｅｎｔｉ ｅｔ ａｌ．: Ｃｈｅｍ Ｂｉｏｌ Ｄｒｕｇ Ｄｅｓ Ｖｏｌ．６７, 2006, ｐ．２０６-２１４
JPN6013025461; Ｎ． Ｋａｌｙａｎａｍ ｅｔ ａｌ．: Ｓｙｎｔｈｅｔｉｃ Ｃｏｍｍｕｎｉｃａｔｉｏｎｓ Ｖｏｌ．１８（１６＆１７）, 1988, ｐ．２１８３-２１９１
Attorney, Agent or Firm:
Hidesaku Yamamoto
Takaaki Yasumura
Natsuki Morishita
Takaaki Yasumura
Natsuki Morishita